CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 24, 2023--Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced approval of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) ...
BOSTON--(BUSINESS WIRE)--Oct 24, 2023--Scorpion Therapeutics, Inc. (鈥淪corpion鈥�), a pioneering clinical-stage oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Jeff Albers as a strategic advisor to ...
NANTES, France--(BUSINESS WIRE)--Oct 23, 2023--Regulatory News:<em>OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</em> today announced that first Phase 1 results for BI 770371, a novel anti-SIRPa monoclonal antibody evaluated in advanced solid tumors, ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--Positive results from the ongoing <a ...
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 23, 2023--Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU庐 (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically meaningful and durable responses, leading to a clinically ...
NEW YORK--(BUSINESS WIRE)--Oct 23, 2023--Flatiron Health today announced a new agreement to bring <a ...